Exclusive: DNA test means patients could be offered most effective treatment first, boosting their chances of beating the disease ...

This marks the first-ever inclusion of ctDNA-MRD testing in these guidelines, representing a significant advancement in lymphoma patient care. "This milestone represents a transformative moment in ...

Serial circulating tumor DNA (ctDNA) testing showed limited clinical benefit in colorectal cancer (CRC) surveillance when frequent imaging is used. The study's retrospective design and small sample ...

SAN FRANCISCO -- Circulating tumor DNA (ctDNA) measurements showed promise for identifying patients with early colorectal cancer (CRC) most likely to benefit from adjuvant therapy, analyses of two ...

ctDNA testing effectively stratifies Merkel cell carcinoma patients into high and low recurrence risk categories, influencing surveillance strategies. The study's cohorts revealed significant ...

Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell carcinoma. Circulating tumor DNA (ctDNA) is not yet standard practice in ...

Researchers from various institutes, along with US biotech company Personalis, have found a test that can predict lung cancer outcomes by identifying circulating tumour DNA (ctDNA) in the blood.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in Clinical Cancer Research, a journal of the American Association ...

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham Cancer Center found that patients with evidence of residual cancer in their ...

Scientists have developed a blood test that can help predict which breast cancer treatment will work best. The team at the ...

Dr. Iseult Browne, a clinical research fellow at the ICR and first author of the study, said: “Our study shows that a simple ...